| Autor: |
Alhajahjeh A; School of Medicine, The University of Jordan, Amman 11190, Jordan.; King Hussein Cancer Center (KHCC), Internal Medicine Department, Amman 11190, Jordan., Al-Faouri R; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02120, USA., Bahmad HF; Arkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA., Bader T; King Hussein Cancer Center (KHCC), Internal Medicine Department, Amman 11190, Jordan., Dobbs RW; Cook County Health and Hospitals System, Chicago, IL 60612, USA., Abdulelah AA; Edinburgh Medical School, The University of Edinburgh, Edinburgh EH8 9YL, UK., Abou-Kheir W; Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon., Davicioni E; Veracyte, Inc., San Francisco, CA 94080, USA., Lee DI; Department of Urology, University of California, Irvine, CA 92868, USA., Shahait M; School of Medicine, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates. |
| Abstrakt: |
Glucagon-like peptide-1 (GLP-1), an incretin hormone renowned for its role in post-meal blood sugar regulation and glucose-dependent insulin secretion, has gained attention as a novel treatment for diabetes through GLP-1 receptor agonists (GLP-1-RA). Despite their efficacy, concerns have been raised regarding the potential associations between GLP-1-RA and certain malignancies, including medullary thyroid cancer. However, evidence of its association with prostate cancer (PCa) remains inconclusive. This review delves into the intricate relationship between GLP-1-RA and PCa, exploring the mechanisms through which GLP-1-Rs may impact PCa cells. We discuss the potential pathways involving cAMP, ERK, AMPK, mTOR, and P27. Furthermore, we underscore the imperative for additional research to elucidate the impact of GLP-1-RA treatment on PCa progression, patient outcomes, and potential interactions with existing therapies. Translational studies and clinical trials are crucial for a comprehensive understanding of the role of GLP-1-RA in PCa management. |
